P

    PRTC (PRTC)

    Official site

    BIOTECHNOLOGY

    $17.42
    +0.00 (+0.00%)

    Last updated: Aug 31, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    86%(12/14)
    Avg Surprise
    -24.77%
    PeriodReportedEst.SurpriseB/MYoY
    Mar 26
    Reported Apr 29
    		$N/AN/AN/ABeat-
    Dec 25
    Reported Apr 29
    		$-26.90$-1.94-1286.60%Miss-7713.9%
    Sep 25
    Reported Dec 3
    		$0.00$0.00N/ABeat-
    Jun 25
    Reported Aug 28
    		$-1.86$-2.04+8.88%Beat-1100.0%
    Mar 25
    Reported Apr 30
    		$0.39$0.00N/ABeat+262.5%
    Dec 24
    Reported Apr 30
    		$0.35N/A+112.48%Beat+340.2%
    Sep 24
    Reported Nov 27
    		$0.00$0.00N/ABeat-
    Jun 24
    Reported Aug 28
    		$-0.15N/A+94.89%Beat-
    Mar 24
    Reported Apr 25
    		$-0.24N/A+87.88%Beat-200.0%
    Dec 23
    Reported Apr 25
    		$-0.15N/A+95.47%Beat-79.6%
    Sep 23
    Reported Nov 29
    		$0.00$0.00N/ABeat-
    Jun 23
    Reported Aug 29
    		$0.00N/A+100.00%Beat+100.0%
    Mar 23
    Reported Apr 28
    		$-0.08N/A+95.45%Beat-260.0%
    Dec 22
    Reported Apr 28
    		$-0.08N/A-124.10%Miss-256.9%
    Sep 22
    Reported Nov 30
    		$0.00$0.00N/ABeat+100.0%
    Jun 22
    Reported Aug 25
    		$-0.10N/A+96.41%Beat+76.0%
    Mar 22
    Reported Apr 21
    		$0.05N/A+101.96%Beat+112.3%
    Dec 21
    Reported Apr 21
    		$0.05N/A+102.13%Beat+125.3%
    Jun 21
    Reported Aug 24
    		$-0.26N/A+88.59%Beat-162.4%
    Mar 21
    Reported Apr 15
    		$-0.41$0.00N/AMiss-129.5%
    Dec 20
    Reported Apr 15
    		$-0.41N/A+79.78%Beat-293.1%
    Sep 20
    Reported Dec 31
    		$-0.21$0.00N/AMiss-135.6%
    Jun 20
    Reported Jun 30
    		$0.42N/AN/ABeat-27.3%
    Mar 20
    Reported Jun 29
    		$1.39$0.00N/ABeat+969.2%
    Dec 19
    Reported Mar 31
    		$0.21$0.00N/ABeat+61.5%
    Sep 19
    Reported Dec 31
    		$0.58$0.00N/ABeat+1004.2%
    Jun 19
    Reported Sep 30
    		$0.58$0.00N/ABeat+1004.2%
    Mar 19
    Reported Jun 30
    		$0.13$0.00N/ABeat+966.7%
    Dec 18
    Reported Mar 31
    		$0.13$0.00N/ABeat+966.7%
    Sep 18
    Reported Dec 31
    		$-0.06$0.00N/AMiss-145.3%
    Jun 18
    Reported Sep 30
    		$-0.06$0.00N/AMiss-145.3%
    Mar 18
    Reported Jun 30
    		$-0.01$0.00N/AMiss+83.3%
    Dec 17
    Reported Mar 31
    		$-0.01$0.00N/AMiss+83.3%
    Sep 17
    Reported Dec 31
    		$0.14$0.00N/ABeat+448.8%
    Jun 17
    Reported Sep 30
    		$0.14$0.00N/ABeat-
    Mar 17
    Reported Jun 30
    		$-0.09$0.00N/AMiss-
    Dec 16
    Reported Mar 31
    		$-0.09$0.00N/AMiss-
    Sep 16
    Reported Dec 31
    		$-0.04$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.62EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROIC10.49%
    Financial Health
    Debt/Equity0.03xInterest Coverage3.37x
    Current Ratio6.59xQuick Ratio6.59x
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$17.42
    SMA 20$17.42
    SMA 50$17.42
    SMA 200$17.23
    EMA 10$17.42
    EMA 20$17.42
    EMA 50$17.40
    EMA 200$17.38

    MACD

    Line: 0.00Signal: 0.00Hist: -0.00

    ADX

    ADX: 11.1+DI: 25.6-DI: 20.5

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down100.0
    PSAR$17.11

    Bollinger Bands

    Upper Band$17.42
    Lower Band$17.42
    %B PositionN/A
    Band Width0.50

    RSI (14-Day)

    Neutral
    51.8

    Momentum Oscillators

    Stoch %KN/A
    Stoch %DN/A
    Williams %RN/A
    ROC (10d)N/A
    MomentumN/A
    CCI (20d)N/A
    MFI (14d)N/A

    Volatility Measures

    ATR (14d)$0.00(0.0%)
    StdDev (20d)N/A
    Hist VolN/A

    Volume Flow

    VWAP$17.42
    OBV1.7K
    AD Line-278.4K
    CMF (20d)N/A

    Volume Metrics

    Avg Vol (20d)N/A
    Vol RatioN/A
    VWMA (20d)N/A

    Pivot Points

    R3$17.42
    R2$17.42
    R1$17.42
    Pivot Point$17.42
    S1$17.42
    S2$17.42
    S3$17.42

    Advanced Oscillators

    TSI3.65
    Ultimate OscN/A
    KSTN/A

    Financial Data

    QuarterMar 2026Dec 2025Jun 2025Mar 2025Dec 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total Revenue$2.80M$2.80M$1.85M$4.03M$4.03M$288,000$178,569$178,569$90,000$3.15M$9.01M$9.01M
    Cost of Revenue$1.65M$1.65M$24.90M$-38,928,000$-38,928,000$38.93M$1.86M$1.86M$21.54M$3.06M$33.93M$33.93M
    Gross Profit$1.15M$1.15M$-23,049,000$42.95M$42.95M$-38,640,000$-1,678,555$-1,678,555$-21,454,500$89,000$-24,918,568$-24,918,568
    Operating Expenses$51.55M$51.55M$24.88M$112.65M$112.65M$27.76M$67.80M$67.80M$10.38M$76.25M$105.53M$105.53M
    R&D$31.55M$31.55M$24.90M$15.35M$15.35M$38.93M$42.75M$42.75M$21.54M$53.15M$71.18M$71.18M
    SG&A$0$20.00M$24.88M$267,000$-267,000$27.76M$13.56M$25.06M$13.56M$23.11M$18.67M$34.35M
    Operating Income$-50,403,289$-50,403,289$-47,931,000$-69,697,000$-69,697,000$-66,397,998$-69,481,440$-69,481,440$-35,019,000$-76,162,000$-101,342,770$-101,342,770
    Interest Income$0$5.95M$7.14M$0$10.94M$11.73M$0$8.22M$0$7.73M$0$5.42M
    Interest Expense$44.66M$44.66M$954,131$1.34M$-1,339,000$11.38M$8.43M$8.43M$0$4.99M$2.09M$2.09M
    Income Before Tax$-66,815,515$-66,815,515$-43,858,000$78.81M$78.81M$-55,031,000$-22,181,323$-22,181,323$-11,180,000$-8,420,000$-25,593,473$-25,593,473
    Income Tax Expense$-1,757,385$-1,757,385$923,000$2.14M$2.14M$-6,147,000$18.57M$18.57M$9.36M$11.81M$-24,370,390$-24,370,390
    Net Income$-64,889,763$-64,889,763$-44,605,000$95.28M$95.28M$-41,773,000$-40,368,639$-40,368,639$-20,346,500$-25,005,000$-23,088,566$-23,088,566
    EBITDA$-48,753,499$-48,753,499$-46,240,000$101.97M$101.97M$-64,584,000$-11,166,558$-11,166,558$-34,016,501$-36,550,500$-18,680,856$-18,680,856
    EBIT$-50,403,289$-50,403,289$-47,932,000$100.21M$100.21M$-66,397,998$-13,023,682$-13,023,682$-35,019,000$-38,081,000$-23,503,954$-48,307,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PRTC

    News

    Why Hemogenyx Pharmaceuticals and PureTech Health Are Back in AIM Focus

    AIM Stocks, specifically Hemogenyx Pharmaceuticals (LSE:HEMO) and PureTech Health (LSE:PRTC), are gaining renewed attention in London. This comes as easing oil prices following geopolitical tensions shift investor focus towards life sciences companies, where sentiment is driven by specific milestones. The article highlights how these two companies serve as key reference points for understanding current market themes in the life sciences sector.

    Kalkine Media•7/27/26•
    Neutral

    PRTC - An asymmetric deep-value biotech incubator trapped in a severe conglomerate discount despite recurring proof of multi-billion dollar asset.

    PureTech Health (PRTC) is presented as a deep-value biotech incubator that faces a significant conglomerate discount despite its successful asset track record. The article highlights several structural reasons for this discount, including its London Stock Exchange listing starving it of US institutional capital, ownership leakage through massive venture rounds in its internal ventures, and a consistent cash burn. The author suggests that without a dual-listing or aggressive share buybacks, the value of its entities will likely remain suppressed under its current UK holding company structure.

    Simply Wall Street•7/18/26•
    Neutral

    PureTech Health: Results of Annual General Meeting

    PureTech Health (LSE: PRTC) announced the results of its Annual General Meeting held on June 10, 2026. All resolutions proposed at the meeting were passed by shareholders, including the approval of the Company's Annual Report and Accounts, Directors’ Remuneration Report, re-election of several directors, reappointment of auditors, and authorization for share-related actions. The company provided detailed poll results for each resolution, outlining votes for, against, and withheld.

    The National Law Review•7/18/26•
    Neutral

    REG - PureTech Health PLC - PDMR Notification RSU Vesting

    PureTech Health plc (PRTC) announced that restricted share units (RSUs) granted to certain directors and PDMRs on June 26, 2024, vested on June 26, 2026, with 33% of the shares subsequently issued on July 14, 2026. The issuance of 123,981 ordinary shares to Eric Elenko, Michael Inbar, and Charles Sherwood was in net settlement of vested RSUs, after deductions for payroll taxes, at a market price of 119.20 pence per share.

    TradingView•7/17/26•
    Neutral

    PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

    PureTech's founded entity, Celea Therapeutics, has dosed the first patient in its global Phase 3 SURPASS-IPF trial for deupirfenidone, targeting idiopathic pulmonary fibrosis (IPF). This trial is the first industry-sponsored head-to-head Phase 3 study in IPF, comparing deupirfenidone to pirfenidone, with topline data expected in late 2029. The trial aims to demonstrate the superiority of deupirfenidone and offers a patient-centric design with no placebo arm for this progressive and fatal lung disease.

    BioSpace•7/14/26•
    Bullish

    Frequently Asked Questions About PRTC

    Does PRTC pay dividends?
    PRTC (PRTC) does not currently pay a regular dividend.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In